Purple Biotech ADR (PPBT)
Purple Biotech ADR is a depositary receipt listed on NASDAQ that represents common stock of Purple Biotech Ltd., a clinical-stage oncology company based in Rehovot, Israel. The underlying company focuses on therapies designed to address tumor immune evasion and drug resistance in cancer. Its pipeline includes CM24, a humanized monoclonal antibody being studied in Phase 2 for pancreatic ductal adenocarcinoma in combination with anti-PD-1 therapy; NT219, a small-molecule candidate in Phase 2 trials for recurrent or metastatic head and neck squamous cell carcinoma and colorectal adenocarcinoma; and CAPTN-3, including IM1240 and IM1305, which is in preclinical development. Purple Biotech also has a collaboration with Bristol Myers Squibb to evaluate CM24 with nivolumab and chemotherapy. The company was formerly known as Kitov Pharma Ltd. and adopted its current name in December 2020.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-PPBT
|
Not available
|
$17
|
942.9% Upside
|
Bargain
|
Fair
|
0.0%
|
0.8x
|
10.106 M
|
4.507 M
|
1.3%
|
99.7%
|
-75.1
|
31.7%
|